BOFA ON BIOCON
Maintain Buy, TP 435 (From 400)
Malaysia follows Benguluru facility-USFDA clears both
To increase confidence for upcoming bio-similar launch pipeline
Annualized revenue to increase from $1bn in H1FY25 to $1.2bn in FY26
Deleveraging and new launch performance now in focus